Types of Immunotherapy For Cancer in India?

In India, a diverse range of immunotherapy options is available, encompassing checkpoint inhibitors, cancer vaccines, and adoptive cell therapy. Oncologists tailor treatment plans to individual patient profiles, ensuring the administration of the most suitable and effective therapy.

• Checkpoint Inhibitors: These drugs block certain proteins on immune cells, enabling the immune system to recognize and attack cancer cells more effectively.
• Cancer Vaccines: Designed to stimulate the immune system, cancer vaccines encourage the body to recognize and target specific cancer cells.
• Adoptive Cell Therapy: This involves extracting immune cells (such as T cells) from the patient, modifying them to enhance their cancer-fighting abilities, and then reintroducing them into the patient’s body.
• Monoclonal Antibodies: Engineered antibodies can target specific proteins on cancer cells, aiding the immune system in recognizing and destroying the cancer.
• Interferons and Interleukins: These signaling proteins enhance the immune system’s response, activating immune cells to attack cancer cells more vigorously.
• Oncolytic Virus Therapy: Certain viruses are modified to selectively infect and kill cancer cells, while sparing normal cells. This approach can stimulate an immune response against the tumor.
• Immune System Modulators: Drugs that modulate the overall activity of the immune system, either by boosting its response or regulating specific pathways involved in immune function.
• Tumor-Infiltrating Lymphocytes (TILs): TILs are immune cells extracted from the tumor, grown in the lab, and then infused back into the patient to enhance the immune response against cancer.
• CAR-T Cell Therapy: Chimeric Antigen Receptor T-cell therapy involves genetically modifying a patient’s own T cells to express a receptor that targets cancer cells, providing a highly targeted approach.
• Dendritic Cell Therapy: Dendritic cells, key regulators of the immune system, are manipulated to stimulate an immune response against cancer when reintroduced into the patient.